Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen

• Päätekijät: Szu-Ting Yang (Tekijä), Wen-Hsun Chang (Tekijä), Fang-Wei Chou (Tekijä), Hung-Hsien Liu (Tekijä), Wen-Ling Lee (Tekijä), Peng-Hui Wang (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2024-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

In the Part I, we have discussed the background of CA125 and the development of anti-CA125 monoclonal antibody (MAb) to highlight the potential role of CA125 and anti-CA125 MAb in the management of women with advanced stage epithelial ovarian cancer (EOC). Glycosylation change either by N-link or by...